SIGN UPLog In

Last deal

$20.5M
Local Amount - SEK 190.M

Amount

Series C

Stage

07.07.2020

Date

2

all rounds

$27.3M

Total amount

General

About Company
Gesynta Pharma develops clinical candidates to improve treatments for serious diseases.

Industry

Sector :

Subsector :

Keywords :

Also Known As

Gesynta

founded date

01.01.2017

Number of employees

1-10

Company Type

For Profit

Last funding type

Series C

IPO status

Private

Description

Gesynta Pharma's next drug candidate, GS-073, is ready to enter clinical phase I in 2023, and the company also explores the use of MPGES-1 inhibition in cardiovascular diseases and cancer. Additionally, Gesynta Pharma's drug candidate GS-248 is in clinical phase II development for the treatment of endometriosis. The company's R&D is based on research from the Karolinska Institutet.
Contacts

location

Stockholm, Sweden

Phone number

Website URL

https://www.gesynta.se/

Social url